Hervé Hoppenot, Incyte CEO (Jeff Rumans)

ODAC echoes FDA con­cern over In­cyte PD-1, as Paz­dur sig­nals broad­er shift for ac­cel­er­at­ed ap­proval

Af­ter the FDA lam­bast­ed their PD-1 ahead of an ad­comm ear­li­er this week, In­cyte ran in­to new trou­ble Thurs­day as ODAC pan­elists vot­ed against an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA